Safety and Retention Rate of the JAK and TNF Inhibitors in Rheumatoid Arthritis: a Real-life Experience
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Chi Chiu Mok, MD, FRCP
- Phone Number: 852-37677844
- Email: ccmok2006@gmail.com
Study Locations
-
-
-
Hong Kong, China, 000
- Department of Medicine, Tuen Mun Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All RA patients in our biologics registry treated with the JAK inhibitors (N=411)
- All RA patients in our biologics registry treated with the TNF inhibitors (N=1392)
Exclusion Criteria:
- RA patients in our biologics registry treated with other biologic/targeted DMARDs
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
JAK inhibitors
RA patients treated with JAK inhibitors
|
TNF inhibitors or the JAK inhibitors
|
|
TNF inhibitors
RA patients treated with TNF inhibitors
|
TNF inhibitors or the JAK inhibitors
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Withdrawal rate due to major / serious adverse events
Time Frame: from start of biologic/targeted DMARD use to these event(s) up to 10 years
|
adverse events eg.
MACEs, malignancy, infections
|
from start of biologic/targeted DMARD use to these event(s) up to 10 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Withdrawal rate due to inefficacy
Time Frame: from start of biologic/targeted DMARD use to last clinic visit up to 10 years
|
Efficacy of the agents in terms of retention rate
|
from start of biologic/targeted DMARD use to last clinic visit up to 10 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HKSRJAK study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.